Bullish Projections for Live Ventures’ (LIVE) Revenues; H.C. Wainwright Foresees Upside in Ocera Therapeutics (OCRX)


Shares of Live Ventures Inc. (Nasdaq:LIVE) soared more than 25% to touch a new 52-week High in pre-market trading Wednesday after the company delivered strong growth in its financial results.

For its full-year fiscal 2016, Live Ventures posted revenues of $79 million, a 136% increase year over year, and net profit of about $17.82 million, or $8.92 per share for the period.

The diversified holding company said it anticipates full-year fiscal 2017 revenue to be over $120 million, representing more than 50% increase versus 2016.

Live Ventures, which focus on acquiring profitable companies that have demonstrated a strong history of earnings power, has 2.79M shares outstanding. At close on Tuesday, the company had a market capitalization of $72.78M and LIVE stock one-year range was between $6.00 and $26.45 per share



Ocera Therapeutics Inc. (Nasdaq:OCRX) shares climbed over 15% before the opening bell Wednesday as analysts at H.C. Wainwright initiated coverage in the company’s stock with a Buy rating and a price target of $10.00, representing a potential upside of 284.61% from the stock’s closing price on Tuesday of $2.20.

Ocera Therapeutics, which focuses on the development and commercialization of OCR-002 for the treatment of hepatic encephalopathy, has 23.14M shares outstanding, market capitalization (intraday) of $50.92M and OCRX stock 52-week range is from $1.76 to $3.90 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/